Windsor Group LTD cut its position in Becton Dickinson and Co (NYSE:BDX) by 4.3% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,188 shares of the medical instruments supplier’s stock after selling 98 shares during the period. Windsor Group LTD’s holdings in Becton Dickinson and were worth $546,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the business. IMS Capital Management purchased a new position in shares of Becton Dickinson and in the 3rd quarter worth about $29,000. Oregon Public Employees Retirement Fund raised its position in shares of Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 6,545,502 shares in the last quarter. Nalls Sherbakoff Group LLC bought a new position in shares of Becton Dickinson and in the 4th quarter worth approximately $34,000. Aspire Private Capital LLC bought a new position in shares of Becton Dickinson and in the 4th quarter worth approximately $39,000. Finally, Sontag Advisory LLC bought a new position in shares of Becton Dickinson and in the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 84.82% of the company’s stock.

In related news, EVP Ribo Alberto Mas sold 2,104 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $255.00, for a total value of $536,520.00. Following the transaction, the executive vice president now directly owns 19,074 shares of the company’s stock, valued at approximately $4,863,870. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Vincent A. Forlenza sold 3,123 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the transaction, the chief executive officer now directly owns 215,372 shares in the company, valued at $54,926,321.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,684 shares of company stock worth $7,518,574. Company insiders own 0.12% of the company’s stock.

Several research analysts have recently issued reports on the company. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Wednesday. Raymond James decreased their target price on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research report on Tuesday, March 19th. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Finally, Piper Jaffray Companies upped their price target on Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 5th. Six research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $255.75.

BDX stock opened at $249.77 on Wednesday. The firm has a market capitalization of $67.20 billion, a PE ratio of 22.69, a PEG ratio of 1.77 and a beta of 1.21. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.58 by $0.12. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period last year, the business posted $2.48 EPS. On average, equities research analysts expect that Becton Dickinson and Co will post 12.09 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 8th were paid a $0.77 dividend. The ex-dividend date was Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.23%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.

COPYRIGHT VIOLATION WARNING: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2019/04/10/windsor-group-ltd-lowers-holdings-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.